NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) filed a Form 8-K on October 5, 2026, announcing preliminary, unaudited financial results for the fiscal quarter and year ended September 30, 2026. The company reported that its fourth fiscal quarter 2026 product revenue was approximately $3.8 million. This figure represents a year-over-year increase of 38.4%, compared to approximately $2.7 million in the same period of the prior fiscal year.
For the full fiscal year 2026, NeuroOne anticipates total product revenue of approximately $10.5 million. This amount reflects a 15.6% year-over-year increase and places the company at the top of its previously issued revenue guidance range of $9.2 million to $10.5 million.
In addition to its revenue figures, the company disclosed the receipt of a significant product purchase order during September 2026. The order is valued at $4.5 million, which the company describes as the largest in its history. Approximately $1.0 million of this order was shipped by September 30, 2026. The remaining $3.6 million is scheduled to begin shipping during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules.
Following the receipt of this order, the company reported that total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million as of September 30, 2026. Management noted that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. The company stated that it enters fiscal 2027 with $5.4 million in open purchase orders and highlighted additional growth drivers, including the commercialization of its trigeminal neuralgia system, international market expansion, and the advancement of its drug delivery platform.
Complete financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission. The company cautions that the preliminary financial information included in the filing is subject to the completion of year-end accounting and audit procedures and is therefore subject to adjustment.
